Therma Bright is a progressive medical diagnostic and device technology company that focuses on providing innovative solutions for today's medical and healthcare challenges. One of their notable products is the smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test, which has been developed to efficiently detect the COVID-19 virus. Therma Bright has been in close collaboration with the U.

S. Food and Drug Administration (FDA) regarding the Emergency Use Authorization (EUA) application process for the AcuVid™ test. The Company's Executive and Product Development teams have worked diligently to address FDA's questions and ensure they meet the application template requirements.

Additionally, Therma Bright has provided comprehensive test data, including clinical performance studies, cross-reactivity tests, and Variants of Concern testing, which have been crucial in demonstrating the efficacy of the AcuVid™ test. The Company eagerly awaits a positive response from the FDA for EUA approval. After securing the FDA approval, Therma Bright plans to apply for regulatory approvals globally based on the data and application answers.

As a forward-thinking company, Therma Bright continues to explore innovative solutions to tackle medical challenges effectively